A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Allergan
- 04 Dec 2017 Planned End Date changed from 9 Sep 2019 to 15 Aug 2019.
- 04 Dec 2017 Planned primary completion date changed from 9 Aug 2019 to 15 Aug 2019.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.